We are a Swiss pharmaceutical company
that offers its products in more than 70
countries around the world.
We focus mainly on the therapeutic areas of ophthalmology, orthopedics, rheumatology and neurology. Clinical trials and the privileged exchange of information with both healthcare professionals and patients are always the cornerstone of our product development. TRB’s expertise relates primarily to the production, packaging and therapeutic possibilities of hyaluronic acid. These skills are evident across our wide range of products and related patents. Our Swiss affiliate, TRB CHEMEDICA SA, is based in Vouvry, Valais. In this site, two production units and a research and development department work closely together. It is also where the entire range of OSTENIL® products is manufactured.
The Swiss portfolio of TRB CHEMEDICA also includes ophthalmic products such as VISMED® Line – eye drops based on hyaluronic acid. Thanks to its unique formulations, this product has set a new benchmark and has become the preferred choice of treating dry eye. In orthopedics and rheumatology, TRB CHEMEDICA has set new standards with the OSTENIL® Line – intra-articular injections for the treatment of traumatic and degenerative joint diseases, such as osteoarthritis. In Switzerland, OSTENIL® was the first product line based on biofermentative hyaluronic acid to be authorised for intra-articular use in all synovial joints. For more than 20 years, the OSTENIL® brand has stood strong for its effectiveness and optimal safety.
Key facts about the company
Malaysian representative office
Kuala Lumpur, Malaysia
Number of employees (worldwide)